Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07735637
What this trial is testing

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Who this might be right for
Newly Diagnosed Multiple Myeloma (NDMM)
AstraZeneca 750
Early research (Phase 1)Active Not RecruitingNCT03774654
What this trial is testing

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRefractory B-Cell Small Lymphocytic LymphomaRelapsed Adult ALL+2 more
Baylor College of Medicine 13
Testing effectiveness (Phase 2)UnknownNCT03398967
What this trial is testing

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
B Cell LeukemiaB Cell Lymphoma
Chinese PLA General Hospital 80
Testing effectiveness (Phase 2)Looking for participantsNCT05826535
What this trial is testing

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin Lymphoma+1 more
Lyell Immunopharma, Inc. 270
Testing effectiveness (Phase 2)UnknownNCT04271410
What this trial is testing

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Who this might be right for
LeukemiaLymphoma, Large B-Cell, DiffuseLeukemia, B-cell+2 more
Chongqing Precision Biotech Co., Ltd 80
Testing effectiveness (Phase 2)Looking for participantsNCT06045910
What this trial is testing

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell+3 more
Cancer Research UK 84
Not applicableActive Not RecruitingNCT07101913
What this trial is testing

Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.

Who this might be right for
Acute Kidney Injury (AKI)Infusion of CD19 CAR T CellB Cell Lymphoma
Hospices Civils de Lyon 300
Early research (Phase 1)UnknownNCT03879382
What this trial is testing

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

Who this might be right for
POMES SyndromeRelapsed and Refractory POMES Syndrome
Hrain Biotechnology Co., Ltd. 10
Early research (Phase 1)UnknownNCT03671460
What this trial is testing

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Tianjin Mycure Medical Technology Co., Ltd 18
Testing effectiveness (Phase 2)Looking for participantsNCT07284433
What this trial is testing

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Lymphoma Diffuse Large B-cellLeukemia and LymphomaLeukemia Relapse+1 more
AvenCell Therapeutics, Inc. 178
Early research (Phase 1)Looking for participantsNCT06691152
What this trial is testing

Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine 18
Very early researchNot Yet RecruitingNCT07674147
What this trial is testing

RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases

Who this might be right for
Autoimmune DiseasesSLE - Systemic Lupus ErythematosusSSc-Systemic Sclerosis+3 more
The Children's Hospital of Zhejiang University School of Medicine 30
Testing effectiveness (Phase 2)Ended earlyNCT02935543
What this trial is testing

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Who this might be right for
Leukemia, Acute Lymphoblastic
University of Pennsylvania 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT04697940
What this trial is testing

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Who this might be right for
Relapsed and Refractory B-cell Non-Hodgkin's LymphomaDecitabine-primed Tandem CD19/CD20 CAR T Cells
Han weidong 33
Very early researchLooking for participantsNCT07203404
What this trial is testing

Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

Who this might be right for
SLELNANCA Associated Vasculitis+6 more
Nanjing Bioheng Biotech Co., Ltd. 96
Testing effectiveness (Phase 2)Study completedNCT01475058
What this trial is testing

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

Who this might be right for
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia+4 more
Fred Hutchinson Cancer Center 1
Early research (Phase 1)Ended earlyNCT06256484
What this trial is testing

Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics 1
Testing effectiveness (Phase 2)UnknownNCT02349698
What this trial is testing

A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Who this might be right for
LeukemiaLymphoma
Southwest Hospital, China 45
Very early researchNot Yet RecruitingNCT05779930
What this trial is testing

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory+3 more
Nationwide Children's Hospital 12
Not applicableUnknownNCT04237428
What this trial is testing

CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 20
Next Page